Br J Haematol . Amelioration of COVID-19 Related Cytokine Storm Syndrome: Parallels to Chimeric Antigen receptor-T Cell Cytokine Release Syndrome

[tetano]

Br J Haematol


. 2020 Jun 25.
doi: 10.1111/bjh.16961. Online ahead of print.
Amelioration of COVID-19 Related Cytokine Storm Syndrome: Parallels to Chimeric Antigen receptor-T Cell Cytokine Release Syndrome


Ryan L Hoiland ^{1 2} , Sophie Stukas ³ , Jennifer Cooper ³ , Sonny Thiara ⁴ , Luke Y C Chen ⁵ , Catherine M Biggs ⁶ , Kevin Hay ⁵ , Agnes Y Y Lee ⁵ , Kamran Shojania ⁷ , Alym Abdulla ⁵ , Cheryl L Wellington ³ , Mypinder S Sekhon ⁴



Affiliations

• PMID: 32584416
• DOI: 10.1111/bjh.16961

Abstract

Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19.